GB201616912D0 - Classification of cancer - Google Patents

Classification of cancer

Info

Publication number
GB201616912D0
GB201616912D0 GBGB1616912.0A GB201616912A GB201616912D0 GB 201616912 D0 GB201616912 D0 GB 201616912D0 GB 201616912 A GB201616912 A GB 201616912A GB 201616912 D0 GB201616912 D0 GB 201616912D0
Authority
GB
United Kingdom
Prior art keywords
cancer
classification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1616912.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of East Anglia
Original Assignee
University of East Anglia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of East Anglia filed Critical University of East Anglia
Priority to GBGB1616912.0A priority Critical patent/GB201616912D0/en
Publication of GB201616912D0 publication Critical patent/GB201616912D0/en
Priority to PCT/EP2017/075368 priority patent/WO2018065525A1/en
Priority to US16/339,463 priority patent/US11746380B2/en
Priority to JP2019518269A priority patent/JP7365899B2/ja
Priority to CA3038743A priority patent/CA3038743A1/en
Priority to AU2017341084A priority patent/AU2017341084B2/en
Priority to EP17780101.6A priority patent/EP3523443B1/en
Priority to JP2022147254A priority patent/JP7539443B2/ja
Priority to US18/347,074 priority patent/US20230349000A1/en
Priority to AU2024200150A priority patent/AU2024200150A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30Unsupervised data analysis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Epidemiology (AREA)
  • Artificial Intelligence (AREA)
  • Databases & Information Systems (AREA)
  • Bioethics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
GBGB1616912.0A 2016-10-05 2016-10-05 Classification of cancer Ceased GB201616912D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB1616912.0A GB201616912D0 (en) 2016-10-05 2016-10-05 Classification of cancer
EP17780101.6A EP3523443B1 (en) 2016-10-05 2017-10-05 Classification and prognosis of cancer
CA3038743A CA3038743A1 (en) 2016-10-05 2017-10-05 Classification and prognosis of cancer
US16/339,463 US11746380B2 (en) 2016-10-05 2017-10-05 Classification and prognosis of cancer
JP2019518269A JP7365899B2 (ja) 2016-10-05 2017-10-05 癌の分類および予後
PCT/EP2017/075368 WO2018065525A1 (en) 2016-10-05 2017-10-05 Classification and prognosis of cancer
AU2017341084A AU2017341084B2 (en) 2016-10-05 2017-10-05 Classification and prognosis of cancer
JP2022147254A JP7539443B2 (ja) 2016-10-05 2022-09-15 癌の分類および予後
US18/347,074 US20230349000A1 (en) 2016-10-05 2023-07-05 Classification and prognosis of cancer
AU2024200150A AU2024200150A1 (en) 2016-10-05 2024-01-10 Classification and prognosis of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1616912.0A GB201616912D0 (en) 2016-10-05 2016-10-05 Classification of cancer

Publications (1)

Publication Number Publication Date
GB201616912D0 true GB201616912D0 (en) 2016-11-16

Family

ID=57571107

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1616912.0A Ceased GB201616912D0 (en) 2016-10-05 2016-10-05 Classification of cancer

Country Status (7)

Country Link
US (2) US11746380B2 (enExample)
EP (1) EP3523443B1 (enExample)
JP (2) JP7365899B2 (enExample)
AU (2) AU2017341084B2 (enExample)
CA (1) CA3038743A1 (enExample)
GB (1) GB201616912D0 (enExample)
WO (1) WO2018065525A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018266632B2 (en) * 2017-05-12 2024-07-25 The Henry M. Jackson Foundation For The Advancement Of Military Medicine. Inc. Prostate cancer gene profiles and methods of using the same
US11894139B1 (en) * 2018-12-03 2024-02-06 Patientslikeme Llc Disease spectrum classification
CN109637589B (zh) * 2018-12-13 2022-07-26 上海交通大学 基于频繁模式和机器学习双推荐制的核定位信号预测方法
GB2612911B (en) * 2019-02-14 2023-11-22 Mirvie Inc Methods and systems for determining a pregnancy-related state of a subject
CN111796095A (zh) * 2019-04-09 2020-10-20 苏州扇贝生物科技有限公司 一种蛋白质组质谱数据处理方法及装置
GB201915464D0 (en) * 2019-10-24 2019-12-11 Uea Enterprises Ltd Novel biomarkers and diagnostic profiles for prostate cancer
EP4204813A4 (en) * 2020-08-28 2024-11-27 The Johns Hopkins University Urinary glycoproteins for the early detection and treatment of aggressive prostate cancer
JP7774310B2 (ja) * 2020-09-30 2025-11-21 国立大学法人 長崎大学 腎がん患者の抗がん剤抵抗性および予後予測方法、抗腎がん物質のスクリーニング方法、ならびに、腎がん治療用医薬組成物
CN112365948B (zh) * 2020-10-27 2023-07-18 沈阳东软智能医疗科技研究院有限公司 癌症分期预测系统
CN116324874A (zh) * 2020-11-06 2023-06-23 威里利生命科学有限责任公司 对前列腺癌预后的人工智能预测
CN114540492A (zh) * 2022-01-10 2022-05-27 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 检测SCN4A和SCN7A mRNA表达量的产品在制备肝癌预后预测产品中的应用
US20250290150A1 (en) * 2022-05-04 2025-09-18 The Regents Of The University Of California Methods and systems for characterization, diagnosis, and treatment of cancer
KR102870357B1 (ko) * 2022-07-21 2025-10-13 인제대학교 산학협력단 인공지능 기술에 기반한 전립선암 조직의 세포 핵의 클러스터 분석 시스템 및 방법
CN117385041A (zh) * 2022-09-03 2024-01-12 昂凯生命科技(苏州)有限公司 用于预测肿瘤进展及预后的基因标志物组合、试剂盒及系统
CN120380170A (zh) * 2022-10-12 2025-07-25 液体活检研究有限责任公司 用于唾液中的前列腺癌检测的方法
CN116298292B (zh) * 2023-03-20 2023-09-08 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) Gng2蛋白的检测试剂在制备诊断和预后结肠癌的产品中的用途
WO2024206889A2 (en) * 2023-03-31 2024-10-03 The Board Of Regents Of The University Of Texas System Microbiome as a biomarker for prostate cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6351666B1 (en) 1998-02-27 2002-02-26 Biofield Corp. Method and apparatus for sensing and processing biopotentials
US7353215B2 (en) 2001-05-07 2008-04-01 Health Discovery Corporation Kernels and methods for selecting kernels for use in learning machines
US20050260572A1 (en) 2001-03-14 2005-11-24 Kikuya Kato Method of predicting cancer
WO2003041562A2 (en) 2001-11-14 2003-05-22 Whitehead Institute For Biomedical Research Molecular cancer diagnosis using tumor gene expression signature
EP1828917A4 (en) 2004-11-12 2012-04-25 Health Discovery Corp BIOMARKERS FOR DETECTING, PREDICTING AND MONITORING PROSTATE DISEASE
US7914988B1 (en) 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
CN101720358A (zh) 2007-02-23 2010-06-02 阿威亚拉德克斯股份有限公司 前列腺癌存活和复发
WO2009067655A2 (en) 2007-11-21 2009-05-28 University Of Florida Research Foundation, Inc. Methods of feature selection through local learning; breast and prostate cancer prognostic markers
CA3256492A1 (en) 2010-01-11 2025-11-29 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
US20150218646A1 (en) 2012-07-20 2015-08-06 Diagnocure Inc Methods, kits and compositions for providing a clinical assessment of prostate cancer
ES2945036T3 (es) 2012-08-16 2023-06-28 Veracyte Sd Inc Pronóstico del cáncer de próstata mediante biomarcadores
US20150329911A1 (en) 2012-10-10 2015-11-19 Institute Of Cancer Research: Royal Cancer Hospital Nucleic acid biomarkers for prostate cancer
WO2014159443A1 (en) 2013-03-14 2014-10-02 Genomedx Biosciences, Inc. Cancer biomarkers and classifiers and uses thereof
HK1219763A1 (zh) 2013-03-15 2017-04-13 Metamark Genetics, Inc. 用於癌症预後的组合物和方法
GB201320061D0 (en) * 2013-11-13 2013-12-25 Electrophoretics Ltd Materials nad methods for diagnosis and prognosis of liver cancer
WO2017062505A1 (en) 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer

Also Published As

Publication number Publication date
US11746380B2 (en) 2023-09-05
JP7365899B2 (ja) 2023-10-20
AU2017341084B2 (en) 2023-11-02
JP2023003422A (ja) 2023-01-11
AU2024200150A1 (en) 2024-01-25
US20230349000A1 (en) 2023-11-02
EP3523443A1 (en) 2019-08-14
US20200263255A1 (en) 2020-08-20
EP3523443B1 (en) 2025-08-20
JP7539443B2 (ja) 2024-08-23
JP2019537108A (ja) 2019-12-19
AU2017341084A1 (en) 2019-04-11
WO2018065525A1 (en) 2018-04-12
CA3038743A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
GB201616912D0 (en) Classification of cancer
HUE050747T2 (hu) Poggyász
IL261959B1 (en) Cancer treatment with tg02
LT3122358T (lt) Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui
GB2535802B (en) An item of luggage
IL260948B (en) Verification of metal objects
IL262342A (en) Cancer treatment methods
IL263835A (en) Exosome-guided treatment of cancer
SG10201913528PA (en) Methods of diagnosing cancer
SG11201701076TA (en) Diagnosis of cancer
GB201602210D0 (en) Detection of cancer
IL277752A (en) Cancer vaccines
IL247940A0 (en) Treatment of cancer damaged by 1brca or resistant cancers
GB201408297D0 (en) Treatment of cancer
EP3122375A4 (en) Breast and ovarian cancer vaccines
IL260814A (en) Cancer treatment
GB2546773B (en) Cancer
GB201508480D0 (en) Cancer
GB2577405B (en) Particle
IL248126A0 (en) Combinations of cancer treatments
GB201417456D0 (en) Treatment of cancer
SG10201603579PA (en) Methods Of Detecting Cancer
GB201622214D0 (en) treatment of cancer
GB201400436D0 (en) Detection of brain cancer
GB201604621D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)